SEGMENT INFORMATION (Tables)

3 Months Ended

Jan. 31, 2021

Segment Reporting [Abstract]

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below:

	Three Months Ended
	January 31,
	2021		2020
	(in millions)
Net Revenue:
Life Sciences and Applied Markets	$	722	$	638
Diagnostics and Genomics	294		249
Agilent CrossLab	532		470
Total net revenue	$	1,548	$	1,357
Segment Income From Operations:
Life Sciences and Applied Markets	$	199	$	158
Diagnostics and Genomics	55		34
Agilent CrossLab	142		119
Total segment income from operations	$	396	$	311

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  

	January 31, 2021		October 31, 2020
	(in millions)
Segment Assets:
Life Sciences and Applied Markets	$	3,148	$	3,143
Diagnostics and Genomics	2,540		2,515
Agilent CrossLab	1,422		1,375
Total segment assets	$	7,110	$	7,033

Reconciliation of segment results to total enterprise results

The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: 

	Three Months Ended
	January 31,
	2021		2020
	(in millions)
Total segment income from operations	$	396	$	311
Transformational initiatives	(11)		(13)
Amortization of intangible assets related to business combinations	(44)		(48)
Acquisition and integration costs	(9)		(13)
Other(1)	(4)		(22)
Interest income	—		3
Interest expense	(19)		(20)
Other income (expense), net	3		21
Income before taxes, as reported	$	312	$	219

(1) For the three months ended January 31, 2020, the other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments.